1. Home
  2. BNL vs ERAS Comparison

BNL vs ERAS Comparison

Compare BNL & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadstone Net Lease Inc.

BNL

Broadstone Net Lease Inc.

N/A

Current Price

$22.39

Market Cap

4.1B

Sector

Real Estate

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

N/A

Current Price

$18.87

Market Cap

4.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNL
ERAS
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.0B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
BNL
ERAS
Price
$22.39
$18.87
Analyst Decision
Buy
Strong Buy
Analyst Count
9
12
Target Price
$20.22
$14.25
AVG Volume (30 Days)
1.9M
5.0M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
5.87%
N/A
EPS Growth
N/A
36.23
EPS
0.24
N/A
Revenue
$454,138,000.00
N/A
Revenue This Year
$7.93
N/A
Revenue Next Year
$5.45
N/A
P/E Ratio
$93.17
N/A
Revenue Growth
5.17
N/A
52 Week Low
$15.77
$1.33
52 Week High
$23.10
$24.28

Technical Indicators

Market Signals
Indicator
BNL
ERAS
Relative Strength Index (RSI) 65.14 58.97
Support Level $19.60 $17.63
Resistance Level $23.10 $21.60
Average True Range (ATR) 0.44 1.29
MACD 0.01 -0.18
Stochastic Oscillator 75.68 41.03

Price Performance

Historical Comparison
BNL
ERAS

About BNL Broadstone Net Lease Inc.

Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: